QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine

Neuropharmacology

Volumn 51, Issue 2, 2006, Pages 251-262

  Brea, José ^a   Castro, Marián ^a   Loza, M Isabel ^a   Masaguer, Christian F ^a   Raviña, Enrique ^a   Dezi, Cristina ^b   Pastor, Manuel ^b   Sanz, Ferran ^b   Cabrero Castel, Araceli ^c   Galán Rodríguez, Beatriz ^d   Fernández Espejo, Emilio ^d   Maldonado, Rafael ^c   Robledo, Patricia ^b,c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Atypical profile; Atypicality; Butyrophenone analogue; Prepulse inhibition test; Schizophrenia; Typical antipsychotics

Indexed keywords

2 [2 (6 FLUOROBENZISOXAZOL 3 YL)PIPERIDINYL]METHYL 1,2,3,4 TETRAHYDRO CARBAZOL 4 ONE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE DERIVATIVE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; QF 2004B; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RECEPTOR AFFINITY; STEREOTYPY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BUTYROPHENONES; CARBAZOLES; CATALEPSY; CHO CELLS; CLOZAPINE; CRICETINAE; CRICETULUS; HUMANS; ISOXAZOLES; MALE; MICE; MODELS, MOLECULAR; MOTOR ACTIVITY; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, DOPAMINE; RECEPTORS, HISTAMINE H1; RECEPTORS, MUSCARINIC; RECEPTORS, SEROTONIN; STARTLE REACTION; STEREOTYPED BEHAVIOR;

EID: 33745957973     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.03.021     Document Type: Article

References (48)

1. Ballesteros J.A., and Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptor. In: Conn P.M., and Sealfon S.C. (Eds). Methods in Neurosciences (1994), Academic Press, San Diego 366-428
2. Barrett J. Anti-psychotic drug effect on the behavior of squirrel monkeys differentially controlled by noxious stimuli. Psychopharmacology 77 (1982) 1-6
3. Berg K.A., Maayani S., Goldfarb J., Scaramellini C., Leff P., and Clarke W.P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 54 (1998) 94-104
4. Brea J., Rodrigo J., Carrieri A., Sanz F., Cadavid M.I., Enguix M.J., Villazón M., Mengod G., Caro Y., Masaguer C.F., Raviña E., Centeno N.B., Carotti A., and Loza M.I. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. J. Med. Chem. 45 (2002) 54-71
5. Case D.A., Pearlman D.A., Caldwell J.M., Cheatman III T.E., Ross W.S., Simmerling C.L., Darden T.A., Merz K.M., Stanton R.V., Cheng A.L., Vincent J.J., Crowley M., Tsui V., Radmer R.J., Duan Y., Pitera J., Massova I., Seibel G.L., Singh U.C., Weiner P.K., and Kollman P.A. AMBER6 (1999), University of California, San Francisco
6. Curzon P., and Decker M.W. Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 22 1 (1998) 129-146
7. Dulawa S.C., and Geyer M.A. Psychopharmacology of prepulse inhibition in mice. Chin. J. Physiol. 39 (1996) 139-146
8. Ellenbroek B.A. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 57 (1993) 1-78
9. Elz S., Kramer K., Pertz H.H., Detert H., ter Laak A.M., Kuhne R., and Schunack W. Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists. J. Med. Chem. 43 (2000) 1071-1084
10. Espadaler J., Fernandez-Fuentes N., Hermoso A., Querol E., Aviles F.X., Sternberg M.J., and Oliva B. ArchDB: automated protein loop classification as a tool for structural genomics. Nucleic Acids Res. 32 (2004) D185-D188
11. Fernandez-Espejo E., and Galan-Rodriguez B. Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor. Psychopharmacology 175 (2004) 220-224
12. Geddes J. Prevention of relapse in schizophrenia. N. Engl. J. Med. 346 (2002) 56-58
13. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156 (2001) 117-154
14. Geyer M.A., McIlwain K.L., and Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol. Psychiatry 7 (2002) 1039-1053
15. Giuliani D., and Ferrari F. Involvement of dopamine receptors in the antipsychotic profile of (-) eticlopride. Physiol. Behav. 61 (1997) 563-567
16. Gonzalez-Gomez J.C., Santana L., Uriarte E., Brea J., Villazon M., Loza M.I., De Luca M., Rivas M.E., Montenegro G.Y., and Fontenla J.A. New arylpiperazine derivatives with high affinity for alpha1A, D2 and 5-HT2A receptors. Bioorg. Med. Chem. Lett. 13 (2003) 175-178
17. Hauber W. Impairments of movement initiation and execution induced by a blockade of dopamine D1 or D2 receptors are reversed by a blockade of N-methyl-d-aspartate receptors. Neuroscience 73 (1996) 121-130
18. Herrick-Davis K., Grinde E., and Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther. 295 (2000) 226-232
19. Knable M.B., and Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11 (1997) 123-131
20. Leucht S., Wahlbeck K., Hamann J., and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (2003) 1581-1589
21. Lynch M.R. Schizophrenia and the D1 receptor: focus on negative symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 16 (1992) 797-832
22. Malone D.T., Long L.E., and Taylor D.A. The effect of SR141716 and apomorphine on sensiromotor gating in Swiss mice. Pharmacol. Biochem. Behav. 77 (2004) 839-845
23. 2C receptors. Eur. J. Med. Chem. 35 (2000) 83-95
24. McCaughran Jr. J., Mahjubi E., Decena E., and Hitzemann R. Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology 134 (1997) 131-139
25. Meltzer H.Y., Matsubara S., and Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251 (1989) 238-246
26. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
27. Meschler J.P., Conley T.J., and Howlett A.C. Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol. Biochem. Behav. 67 (2000) 567-573
28. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10 (2005) 79-104
29. Morimoto T., Hashimoto K., Yasumatsu H., Tanaka H., Fujimura M., Kuriyama M., Kimura K., Takehara S., and Yamagami K. Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H- [1] benzothieno [2,3-b] [1, 5]benzodiazepine maleate). Neuropsychopharmacology 26 (2002) 456-467
30. Olivier B., Leahy C., Mullen T., Paylor R., Groppi V.E., Sarnyai Z., and Brunner D. The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?. Psychopharmacology 156 (2001) 284-290
31. Ouagazzal A.M., Jenck F., and Moreau J.L. Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity?. Psychopharmacology 156 (2001) 273-283
32. Owen J.M., O'Donovan M.C., and Gottesman I.I. Schizophrenia. In: McGuffin P., Owen M.J., and Gottesman I.I. (Eds). Psychiatric Genetics and Genomics. first ed. (2002), Oxford University Press, Oxford 247-266
33. Owens D.G. Adverse effects of antipsychotic agents. Do newer agents offer advantages?. Drugs 51 (1996) 895-930
34. Palczewski K. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 278 (2000) 739-745
35. Ralph-Williams R.J., Lehmann-Masten V., Otero-Corchon V., Low M.J., and Geyer M.A. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J. Neurosci. 22 (2002) 9604-9611
36. Ralph-Williams R.J., Lehmann-Masten V., and Geyer M.A. Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology 28 (2003) 108-118
37. Rauser L., Savage J.E., Meltzer H.Y., and Roth B.L. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J. Pharmacol. Exp. Ther. 299 (2001) 83-89
38. 2C) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics. J. Med. Chem. 42 (1999) 2774-2797
39. 2C) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics. J. Med. Chem. 43 (2000) 4678-4693
40. Roth B.L., Willins D.L., Kristiansen K., and Kroeze W.K. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol. Ther. 79 (1998) 231-257
41. Roth B.L., Hanizavareh S.M., and Blum A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl.) 174 (2004) 17-24
42. Roth B.L., Sheffler D.J., and Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3 (2004) 353-359
43. Russig H., Spooren W., Durkin S., Feldon J., and Yee B.K. Apomorphine-induced disruption of prepulse inhibition that can be normalised by systemic haloperidol is insensitive to clozapine pretreatment. Psychopharmacology 175 (2004) 143-147
44. Sali A., and Blundell T.L. Comparative protein modeling by satisfaction of spatial restraints. J. Mol. Biol. 234 (1993) 779-815
45. Serretti A., De Ronchi D., Lorenzi C., and Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr. Med. Chem. 11 (2004) 343-358
46. 2C receptors. Behav. Pharmacol. 6 (1995) 839-842
47. Valverde O., Maldonado R., Valjent E., Zimmer A.M., and Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J. Neurosci. 20 (2000) 9284-9289
48. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Improved protein-ligand docking using GOLD. Proteins Struct. Funct. Genet. 52 (2003) 609-623